0000000000149492

AUTHOR

S. Sallì

showing 4 related works from this author

Fibromyalgia and arthritides

2012

Fibromyalgia (FM) is a chronic pain syndrome that affects at least 2% of the adult population. It is characterised by widespread pain, fatigue, sleep alterations and distress, and emerging evidence suggests a central nervous system (CNS) malfunction that increases pain transmission and perception. FM is often associated with other diseases that act as confounding and aggravating factors, such as rheumatoid arthritis (RA), spondyloarthritides (SpA), osteoarthritis (OA) and thyroid disease. Mechanism-based FM management should consider both peripheral and central pain, including effects due to cerebral input and that come from the descending inhibitory pathways. Rheumatologists should be able…

medicine.medical_specialtylcsh:Internal medicineCentral nervous systemlcsh:MedicineOsteoarthritisSeverity of Illness IndexArthritis RheumatoidDiagnosis DifferentialRheumatologyQuality of lifeFibromyalgiaOsteoarthritisSpondylarthritismedicineHumanspainAggravating Factorlcsh:RC31-1245FatiguePain Measurementbusiness.industryArthritisThyroid diseaselcsh:Rmedicine.diseaseThyroid DiseasesArthritides pain fibromyalgia rheumatic diseasesarthritidesDistressmedicine.anatomical_structurearthritides; fibromyalgia; pain; rheumatic diseasesRheumatoid arthritisPhysical therapyrheumatic diseasesfibromyalgiaChronic Painbusiness
researchProduct

Different effects of biological drugs in rheumatoid arthritis

2013

Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity. Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) t…

Cartilage Articularmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsImmunologyArthritisPharmacologyArthritis Rheumatoidchemistry.chemical_compoundChondrocytesPharmacotherapyTocilizumabDrug TherapyRheumatoidInternal medicinemedicineHumansImmunology and AllergyArthritis Rheumatoid; Cartilage Articular; Chondrocytes; Drug Therapy Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Inflammation Mediators; Pharmaceutical Preparations; Randomized Controlled Trials as Topic; Tumor Necrosis Factor-alphaAdverse effectRandomized Controlled Trials as TopicTumor Necrosis Factor-alphabusiness.industryArthritisAbataceptmedicine.diseaseClinical trialCartilagePharmaceutical PreparationschemistryRheumatoid arthritisCombinationDrug Therapy CombinationRituximabInflammation MediatorsbusinessArticularmedicine.drugAutoimmunity Reviews
researchProduct

AB0427 Clinical and laboratory findings in patients with late-onset sle and correlations with il6 concentrations

2013

Background Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease that usually develops in women aged 18-50 years. It is known that age at onset modifies the clinical manifestations of SLE, and so the elderly may form a specific patient subgroup. It is now well established that the serum levels of the cytokines interleukin (IL) 6 and IL10 are increased in patients with SLE (1). Objectives The primary aim was to compare the type of clinical involvement and autoantibodies in patients with late-onset (LO) or early-onset (EO) SLE. The second aim was to compare IL6 levels in the two patient groups and their possible correlations with clinical and immunological manifestations. Meth…

medicine.medical_specialtySystemic lupus erythematosusAnti-nuclear antibodybusiness.industryImmunologyAutoantibodyArthritismedicine.diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyRheumatologyRheumatologyimmune system diseasesInternal medicineImmunologymedicineImmunology and AllergyAge of onsetmedicine.symptomskin and connective tissue diseasesMalar rashbusinessSerositisAnnals of the Rheumatic Diseases
researchProduct

Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

2013

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…

medicine.medical_specialtyImmunologyArthritisLung biopsyGastroenterologyPulmonary function testingArthritis RheumatoidAntibodies Monoclonal Murine-DerivedPatient Education as TopicUsual interstitial pneumoniaInternal medicinemedicineHumansImmunology and AllergyAntibodies BlockingPneumonitisLeflunomideClinical Trials as TopicTumor Necrosis Factor-alphabusiness.industryInterstitial lung diseaseIsoxazolesmedicine.diseaserespiratory tract diseasesMethotrexateAntirheumatic AgentsRheumatoid arthritisImmunologyLung Diseases InterstitialRituximabbusinessLeflunomidemedicine.drugExpert Review of Clinical Immunology
researchProduct